Zhuhai Sailong Pharmaceutical Co Ltd (002898) - Net Assets
Based on the latest financial reports, Zhuhai Sailong Pharmaceutical Co Ltd (002898) has net assets worth CN¥377.94 Million CNY (≈ $55.30 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥855.28 Million ≈ $125.15 Million USD) and total liabilities (CN¥477.34 Million ≈ $69.85 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 002898 tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥377.94 Million |
| % of Total Assets | 44.19% |
| Annual Growth Rate | 10.82% |
| 5-Year Change | -31.85% |
| 10-Year Change | 50.98% |
| Growth Volatility | 42.6 |
Zhuhai Sailong Pharmaceutical Co Ltd - Net Assets Trend (2013–2025)
This chart illustrates how Zhuhai Sailong Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. See 002898 defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Zhuhai Sailong Pharmaceutical Co Ltd (2013–2025)
The table below shows the annual net assets of Zhuhai Sailong Pharmaceutical Co Ltd from 2013 to 2025. For live valuation and market cap data, see 002898 market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥384.15 Million ≈ $56.21 Million |
-23.06% |
| 2024-12-31 | CN¥499.28 Million ≈ $73.06 Million |
-6.83% |
| 2023-12-31 | CN¥535.88 Million ≈ $78.42 Million |
+1.81% |
| 2022-12-31 | CN¥526.35 Million ≈ $77.02 Million |
-6.62% |
| 2021-12-31 | CN¥563.66 Million ≈ $82.48 Million |
-3.98% |
| 2020-12-31 | CN¥587.00 Million ≈ $85.90 Million |
-10.93% |
| 2019-12-31 | CN¥659.02 Million ≈ $96.44 Million |
-0.68% |
| 2018-12-31 | CN¥663.54 Million ≈ $97.10 Million |
+7.26% |
| 2017-12-31 | CN¥618.64 Million ≈ $90.53 Million |
+143.13% |
| 2016-12-31 | CN¥254.45 Million ≈ $37.23 Million |
+19.35% |
| 2015-12-31 | CN¥213.20 Million ≈ $31.20 Million |
+51.69% |
| 2014-12-31 | CN¥140.55 Million ≈ $20.57 Million |
+25.53% |
| 2013-12-31 | CN¥111.97 Million ≈ $16.38 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Zhuhai Sailong Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 200.1% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CN¥484.58 Million | 127.47% |
| Total Equity | CN¥380.15 Million | 100.00% |
Zhuhai Sailong Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Zhuhai Sailong Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ButOne Information Corp XiAn
SHG:600455
|
$213.77 Million |
|
Immersion Corporation
NASDAQ:IMMR
|
$213.83 Million |
|
T'way Air Co Ltd
KO:091810
|
$213.85 Million |
|
Akmerkez Gayrimenkul Yatirim Ortakligi AS
IS:AKMGY
|
$213.87 Million |
|
ASIX Electronics
TWO:3169
|
$213.73 Million |
|
Asia Paper
KO:002310
|
$213.67 Million |
|
Chen Full International Co Ltd
TWO:8383
|
$213.60 Million |
|
Azkoyen
MC:AZK
|
$213.59 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zhuhai Sailong Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 499,277,281 to 380,149,512, a change of -119,127,769 (-23.9%).
- Net loss of 121,170,019 reduced equity.
- Dividend payments of 6,301,473 reduced retained earnings.
- Other comprehensive income decreased equity by 29,891,464.
- Other factors increased equity by 38,235,187.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-121.17 Million | -31.87% |
| Dividends Paid | CN¥6.30 Million | -1.66% |
| Other Comprehensive Income | CN¥-29.89 Million | -7.86% |
| Other Changes | CN¥38.24 Million | +10.06% |
| Total Change | CN¥- | -23.86% |
Book Value vs Market Value Analysis
This analysis compares Zhuhai Sailong Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.84x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 8.70x to 3.84x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | CN¥0.95 | CN¥8.30 | x |
| 2014-12-31 | CN¥1.18 | CN¥8.30 | x |
| 2015-12-31 | CN¥1.68 | CN¥8.30 | x |
| 2016-12-31 | CN¥1.93 | CN¥8.30 | x |
| 2017-12-31 | CN¥4.33 | CN¥8.30 | x |
| 2018-12-31 | CN¥3.76 | CN¥8.30 | x |
| 2019-12-31 | CN¥3.75 | CN¥8.30 | x |
| 2020-12-31 | CN¥3.33 | CN¥8.30 | x |
| 2021-12-31 | CN¥3.20 | CN¥8.30 | x |
| 2022-12-31 | CN¥2.99 | CN¥8.30 | x |
| 2023-12-31 | CN¥3.05 | CN¥8.30 | x |
| 2024-12-31 | CN¥2.84 | CN¥8.30 | x |
| 2025-12-31 | CN¥2.16 | CN¥8.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zhuhai Sailong Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -31.87%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -23.36%
- • Asset Turnover: 0.62x
- • Equity Multiplier: 2.19x
- Recent ROE (-31.87%) is below the historical average (6.09%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 40.97% | 20.73% | 1.19x | 1.66x | CN¥34.68 Million |
| 2014 | 20.06% | 15.83% | 0.94x | 1.35x | CN¥14.14 Million |
| 2015 | 29.70% | 26.66% | 0.90x | 1.24x | CN¥42.00 Million |
| 2016 | 24.07% | 23.94% | 0.84x | 1.20x | CN¥35.80 Million |
| 2017 | 10.43% | 17.71% | 0.51x | 1.16x | CN¥2.64 Million |
| 2018 | 9.18% | 13.96% | 0.58x | 1.14x | CN¥-5.45 Million |
| 2019 | 4.17% | 9.37% | 0.35x | 1.27x | CN¥-38.42 Million |
| 2020 | -11.45% | -55.70% | 0.15x | 1.39x | CN¥-125.92 Million |
| 2021 | -4.14% | -9.45% | 0.28x | 1.57x | CN¥-79.71 Million |
| 2022 | -7.09% | -14.12% | 0.31x | 1.61x | CN¥-89.95 Million |
| 2023 | 1.78% | 3.07% | 0.38x | 1.52x | CN¥-44.05 Million |
| 2024 | -6.64% | -12.58% | 0.33x | 1.62x | CN¥-83.07 Million |
| 2025 | -31.87% | -23.36% | 0.62x | 2.19x | CN¥-159.18 Million |
Industry Comparison
This section compares Zhuhai Sailong Pharmaceutical Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,796,003,820
- Average return on equity (ROE) among peers: -1.04%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zhuhai Sailong Pharmaceutical Co Ltd (002898) | CN¥377.94 Million | 40.97% | 1.26x | $213.76 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $89.81 Million | 2.75% | 1.57x | $53.47 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $205.14 Million | 10.08% | 0.94x | $1.58 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $144.30 Million | -93.32% | 1.86x | $380.55 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $156.83 Million | 24.69% | 0.38x | $473.06 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.65 Billion | 1.65% | 0.84x | $1.59 Billion |
| Hualan Biological EngineeringInc (002007) | $550.80 Million | 9.54% | 0.27x | $3.43 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $269.70 Million | 9.75% | 0.10x | $1.12 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $11.49 Billion | 5.29% | 0.03x | $4.56 Billion |
| Baolingbao Biology Co Ltd (002286) | $1.51 Billion | 3.27% | 0.28x | $507.88 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $1.89 Billion | 15.89% | 0.21x | $1.66 Billion |
About Zhuhai Sailong Pharmaceutical Co Ltd
Sailong Pharmaceutical Group Co.,Ltd. researches, develops, produces, markets, and services pharmaceutical intermediates, raw materials, and preparations in China. The company offers esomeprazole sodium, ornithine aspartate, thymus, argatroban, tigecycline, monosialotetrahexose ganglioside sodium, cerebroprotein hydrolysate, milrinone, parecoxib sodium, tranexamic acid, clindamycin phosphate, pan… Read more